AstraZeneca's CEO wants to tap into China's innovation explosion. The company inked an oncology antibody deal with Harbour ...
Over the years, melanoma has become a popular testing ground for researchers to explore new immuno-oncology approaches. | ...
The Bavencio-Inlyta combo showed a favorable trend, reducing the risk of death by 14% compared with Pfizer’s Sutent as a ...
Oncologists have a shopping CAR-T full of complaints, with safety questions for cell therapies No. 1
That’s according to a new survey and report from IQVIA, timed to come out alongside this year’s American Society of Clinical ...
After a report of leaking product, Pfizer’s Hospira unit is pulling five lots of sterile injectable medicines from ...
As Johnson & Johnson sorts through a mountain of litigation claiming its talcum-based powders caused users to develop cancers ...
Over the last four years, with President Joe Biden milking a popular cause as an opponent of Big Pharma drug pricing, the ...
Eli Lilly has in the past few months unveiled two back-to-back trial flops for Verzenio in prostate cancer. Now, we know ...
Apellis Pharmaceuticals is taking a slow and steady approach to advertising Syfovre, its treatment for geographic atrophy (GA ...
MilliporeSigma, the Massachusetts-based contract manufacturing arm of Merck KGaA, is increasing its presence in the gene ...
Japan’s AGC Biologics and contract manufacturing specialist BioConnection are teaming up to offer drug development and ...
In the first personal injury case that has gone to trial over Zantac, GSK and Boehringer Ingelheim have emerged with an important victory as a Chicago jury has rejected the claim of Angela Valadez ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results